<DOC>
	<DOC>NCT01203098</DOC>
	<brief_summary>The objective of this study is to compare the efficacy, safety of DU-176b 30mg or DU-176b 15mg versus enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.</brief_summary>
	<brief_title>A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Embolism and Thrombosis</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Enoxaparin</mesh_term>
	<criteria>1. Patients undergoing unilateral total hip arthroplasty 2. Patients who are 2084 years olds 1. Subjects with risks of hemorrhage 2. Subjects with thromboembolic risks 3. Subjects who weigh less than 40 kg 4. Subjects who are pregnant or suspect pregnancy, or subjects who want to become pregnant</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>prevention</keyword>
	<keyword>venous thromboembolism</keyword>
	<keyword>edoxaban</keyword>
	<keyword>anticoagulants</keyword>
</DOC>